MORRISVILLE, N.C.--(BUSINESS WIRE)--Sapheon Inc. announced completed enrollment and first follow-up data in its European Sapheon Closure System Observational ProspectivE (eSCOPE) study. The single-arm, multi-center post-market study includes nine physicians at seven sites treating 67 patients from the UK, Germany, Demark and The Netherlands. Sapheon’s VenaSeal treatment uses a proprietary medical adhesive and delivery system to close the saphenous vein, eliminating the need for surgery, ablation, sedatives, anesthesia, post procedure compression stockings, and the use of chemical sclerosants.
